Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic

American Journal of Alzheimer's Disease and other Dementias

Volumn 30, Issue 6, 2015, Pages 599-606

  Patricio, Chrem Mendez ^a   Gabriela, Cohen ^a   Julieta, Russo Maria ^a   Marcos, Fernandez Suarez ^a   Federico, Nahas ^a   Griselda, Russo ^a   Claudio, Wierszylo ^a   Santiago, Paz ^a   Leonardo, Tabaschi ^a   Jorge, Campos ^a   Alejandra, Amengual ^a   Janus, Kremer ^a   Salvador, Guinjoan ^a   Ramon, Leiguarda ^a   Gustavo, Sevlever ^a   Silvia, Vázquez ^a   Ricardo, Allegri ^a  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

11C PIB PET; amyloid; memory clinic; neuroimaging

Indexed keywords

PITTSBURGH COMPOUND B; AMYLOID BETA PROTEIN; BENZOTHIAZOLE DERIVATIVE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ARTICLE; BRAIN CORTEX ATROPHY; CONTROLLED STUDY; DEMENTIA; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MOLECULAR IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMARY PROGRESSIVE APHASIA; RETROSPECTIVE STUDY; VASCULAR AMYLOIDOSIS; APHASIA, PRIMARY PROGRESSIVE; ATROPHY; BRAIN CORTEX; CEREBRAL AMYLOID ANGIOPATHY; FRONTOTEMPORAL LOBAR DEGENERATION; METABOLISM; PATHOLOGY; STANDARDS;

AGED; ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PEPTIDES; APHASIA, PRIMARY PROGRESSIVE; ATROPHY; BENZOTHIAZOLES; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL CORTEX; DEMENTIA; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 84939135117     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317515576387     Document Type: Article

References (46)

1. Jack CR, Knopman DS, Jagust WJ,. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9 (1): 119-128. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2819840&tool=pmcentrez&rendertype=abstract (. accessed February 21, 2014).
2. Ikonomovic MD, Klunk WE, Abrahamson EE,. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008; 131 (pt 6): 1630-1645. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2408940&tool=pmcentrez&rendertype=abstract (. accessed February 28, 2014).
3. Tolboom N, van der Flier WM, Boverhoff J,. Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry. 2010; 81 (8): 882-884. http://www.ncbi.nlm.nih.gov/pubmed/20543188 (. accessed March 9, 2014).
4. Johnson KA, Minoshima S, Bohnen NI,. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013; 9 (1): e-1-16. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3733252&tool=pmcentrez&rendertype=abstract (. accessed March 9, 2014).
5. Ossenkoppele R, Prins ND, Pijnenburg Y,. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013; 9 (4): 414-421. http://www.ncbi.nlm.nih.gov/pubmed/23164552 (. accessed March 9, 2014).
6. Wolk DA,. Amyloid imaging in atypical presentations of Alzheimer's disease. Curr Neurol Neurosci Rep. 2013; 13 (12): 412. http://www.ncbi.nlm.nih.gov/pubmed/24136459 (. accessed March 9, 2014).
7. Folstein MF, Folstein SE, McHugh PR,. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12 (3): 189-198. http://www.ncbi.nlm.nih.gov/pubmed/1202204 (. accessed March 9, 2014).
8. Wechsler D., Wechsler Memory Scale. New York: The Psychological Corporation; 1987.
9. Schoenberg MR, Dawson KA, Duff K, Patton D, Scott JG, Adams RL,. Test performance and classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples. Arch Clin Neuropsychol. 2006; 21 (7): 693-703. http://www.ncbi.nlm.nih.gov/pubmed/16987634 (. accessed January 27, 2014).
10. Serrano C, Allegri RF, Drake M,. A shortened form of the Spanish Boston naming test: a useful tool for the diagnosis of Alzheimer's disease [in Spanish]. Rev Neurol. 2001; 33 (7): 624-647. http://www.ncbi.nlm.nih.gov/pubmed/11784949 (. accessed March 9, 2014).
11. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G,. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989; 39 (9): 1159-1165.
12. Wechsler D,. Wechsler Memory Scale. 3rd ed. San Antonio: TX Psychol Corp; 1997.
13. Tombaugh TN,. Trail making test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19 (2): 203-2014. http://www.ncbi.nlm.nih.gov/pubmed/15010086 (. accessed January 30, 2014).
14. Dubois BSAPBLI. The FAB: a frontal assessment battery at bedside. Neurology. 2000; 55 (11): 1613-1620.
15. McKhann GM, Knopman DS, Chertkow H,. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7 (3): 263-269. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3312024&tool=pmcentrez&rendertype=abstract (. accessed November 8, 2013).
16. Rascovsky K, Hodges JR, Knopman D,. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134 (pt 9): 2456-2477. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3170532&tool=pmcentrez&rendertype=abstract (. accessed November 7, 2013).
17. Mesulam MM,. Primary progressive aphasia-a language-based dementia. N Engl J Med. 2003; 349 (16): 1535-1542. http://www.ncbi.nlm.nih.gov/pubmed/14561797 (. accessed October 16, 2003).
18. Gorno-Tempini ML, Hillis a E, Weintraub S,. Classification of primary progressive aphasia and its variants. Neurology. 2011; 76 (11): 1006-1014. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3059138&tool=pmcentrez&rendertype=abstract (. accessed March 15, 2011).
19. Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC,. Posterior cortical atrophy. Lancet Neurol. 2012; 11 (2): 170-178. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3740271&tool=pmcentrez&rendertype=abstract (. accessed February 23, 2014).
20. Knudsen KA, Rosand J, Karluk D, Greenberg SM,. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001; 56 (4): 537-539. http://www.ncbi.nlm.nih.gov/pubmed/11222803 (. accessed March 17, 2014).
21. Russo MJ, Gustafson D, Vázquez S,. Creation of the Argentina-Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 2014; 10 (1): S84-S87. http://linkinghub.elsevier.com/retrieve/pii/S1552526013029166 (. accessed March 14, 2014).
22. Albert MS, DeKosky ST, Dickson D,. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7 (3): 270-279. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3312027&tool=pmcentrez&rendertype=abstract (. accessed November 8, 2013).
23. Koivunen J, Scheinin N, Virta JR,. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011; 76 (12): 1085-1090. http://www.ncbi.nlm.nih.gov/pubmed/21325653 (. accessed June 8, 2014).
24. Dubois B, Feldman HH, Jacova C,. Revising the definition ofAlzheimer's disease: a new lexicon. Lancet Neurol. 2010; 9 (11): 1118-1127. http://www.ncbi.nlm.nih.gov/pubmed/20934914 (. accessed February 19, 2014).
25. Summary E,. The benefits of early diagnosis and intervention World Alzheimer Report 2011; 2011.
26. Yang L, Rieves D, Ganley C,. Brain amyloid imaging-FDA approval of florbetapir F18 injection. N Engl J Med. 2012; 367 (10): 885-887. http://www.ncbi.nlm.nih.gov/pubmed/22931256 (. accessed March 15, 2014).
27. Clark CM, Schneider JA, Bedell BJ,. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011; 305 (3): 275-283. http://www.ncbi.nlm.nih.gov/pubmed/21245183 (. accessed February 19, 2014).
28. Klunk WE,. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011; 32 (suppl 1): S20-S36. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3233688&tool=pmcentrez&rendertype=abstract (. accessed February 28, 2014).
29. Cairns NJ, Ikonomovic MD, Benzinger T,. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009; 66 (12): 1557-1562. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2796200&tool=pmcentrez&rendertype=abstract (. accessed March 9, 2014).
30. Piguet O, Halliday GM, Creasey H, Broe GA, Kril JJ,. Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. Int Psychogeriatr. 2009; 21 (4): 688-695. http://www.ncbi.nlm.nih.gov/pubmed/19493380 (. accessed March 9, 2014).
31. Harms M, Benitez BA, Cairns N,. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol. 2013; 70 (6): 736-741. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3681841&tool=pmcentrez&rendertype=abstract (. accessed December 3, 2014).
32. Warren JD, Fletcher PD, Golden HL,. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol. 2012; 8 (8): 451-464. http://www.ncbi.nlm.nih.gov/pubmed/22801974 (. accessed November 7, 2013).
33. Rascovsky K, Hodges JR, Kipps CM,. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord. 2007; 21 (4): S14-S18. http://www.ncbi.nlm.nih.gov/pubmed/18090417.
34. Johnson JK, Head E, Kim R, Starr A,. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999; 56 (10): 1233-1239.
35. Grossman M,. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol. 2010; 6 (2): 88-97. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3637977&tool=pmcentrez&rendertype=abstract (. accessed November 7, 2013).
36. Gorno-Tempini ML, Hillis AE, Weintraub S,. Classification of primary progressive aphasia and its variants. Neurology. 2011; 76 (11): 1006-1014. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3059138&tool=pmcentrez&rendertype=abstract (. accessed February 26, 2014).
37. Gorno-Tempini ML, Dronkers NF, Rankin KP,. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004; 55 (3): 335-346. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2362399&tool=pmcentrez&rendertype=abstract (. accessed March 9, 2014).
38. Pike KE, Savage G, Villemagne VL,. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130 (pt 11): 2837-2844. http://www.ncbi.nlm.nih.gov/pubmed/17928318 (. accessed February 22, 2014).
39. Morris JC, Roe CM, Xiong C,. APOE predicts Aβ but not tau Alzheimer's pathology in cognitively normal aging ccess. Ann Neurol. 2011; 67 (1): 122-131.
40. Storandt M, Mintun MA, Head D, Morris JC,. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009; 66 (12): 1476-1481.
41. Sperling RA, Aisen PS, Beckett LA,. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7 (3): 280-292. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3220946&tool=pmcentrez&rendertype=abstract (. accessed November 8, 2013).
42. Desikan RS, McEvoy LK, Thompson WK,. Amyloid-β-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012; 69 (6): 709-713. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3423526&tool=pmcentrez&rendertype=abstract (. accessed June 8, 2014).
43. Gomperts SN, Rentz DM, Moran E,. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008; 71 (12): 903-910. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2637553&tool=pmcentrez&rendertype=abstract (. accessed January 21, 2014).
44. Burrell JR, Hornberger M, Villemagne VL, Rowe CC, Hodges JR,. Clinical profile of PiB-positive corticobasal syndrome. PLoS One. 2013; 8 (4): e61025. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3618463&tool=pmcentrez&rendertype=abstract (. accessed February 24, 2014).
45. Hassan A, Whitwell JL, Josephs KA,. The corticobasal syndrome-Alzheimer's disease conundrum. Expert Rev Neurother. 2011; 11 (11): 1569-1578. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3232678&tool=pmcentrez&rendertype=abstract (. accessed March 15, 2014).
46. Fleisher AS, Chen K, Liu X,. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011; 68 (11): 1404-1411. http://www.ncbi.nlm.nih.gov/pubmed/21747008 (. accessed March 9, 2014).